D
DNALite
Biotech & Life Sciences · San Francisco, United States · Founded 2016
An early-stage preclinical biotechnology company that is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies MoreLess
DNAlite Therapeutics, Inc. is an early-stage preclinical biotechnology company focused on developing innovative gene therapies. The company leverages proprietary vector technology to create oral and non-immunogenic medicines aimed at overcoming the limitations of current biological treatments. DNAlite's primary objective is to modify the gastrointestinal (GI) tract to restore its functionality in patients with genetic diseases or compromised mucosa. By targeting GI cells with DNA and RNA, the company aims to address both intestinal and systemic diseases. DNAlite operates in the biotechnology sector, serving patients with genetic and GI-related conditions. Its business model revolves around the research and development of novel gene therapies, with revenue generation expected from licensing agreements, partnerships, and eventual commercialization of its therapeutic products.
Keywords: gene therapy, biotechnology, gastrointestinal, non-immunogenic, vector technology, genetic diseases, preclinical, oral administration, systemic diseases, innovative medicines.
Company overview
DNALite company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Francisco, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 83.5
Valuation & funding
DNALite funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| CONVERTIBLEEquity / VC | Mar 2023 | $0 | — | SOSV · Indie Bio | — |
| EARLY VC✓Equity / VC | May 2022 | $8.9M | $36M | Undisclosed | ↗ |
| GRANTOther financing | Dec 2021 | $970K | — | US National Science Foundation | ↗ |
| SEED✓Equity / VC | Jun 2019 | — | — | SOSV | — |
| GRANTOther financing | Jan 2019 | $220K | — | US National Science Foundation | — |
| SEED✓Equity / VC | Aug 2018 | Berkeley Catalyst Fund · SOSV · Blue Bear Ventures | ↗ | ||
| SEED✓Equity / VC | Apr 2017 | SOSV · Indie Bio | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 7 |
| 2025 | 7 |
| 2024 | 4 |
| 2023 | 6 |
| 2022 | 7 |
| 2021 | 10 |
| 2020 | 7 |
Growth signals
DNALite website traffic
Latest recorded traffic for DNALite is 270 monthly website visits, up 12.5% over the last three months. DNALite's team grew 0% over the past year.
Comparisons
DNALite compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
DNALite's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where DNALite has talent and traffic
team presence
In the news
Latest news about DNALite
Recent press, funding announcements, and product moves mentioning DNALite — open to read from the original sources.
Market sentiment
What the market is saying about DNALite
An AI-synthesized read of the highest-engagement posts about DNALite on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DNALite’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.